FR2390408A1 - Procede de marquage par un isotope radioactif d'un sel hydrosoluble d'oxine, ou de ses derives halogenes ou sulfones, produits ainsi marques, procede de marquage des elements figures du sang, et medicaments ainsi obtenus - Google Patents

Procede de marquage par un isotope radioactif d'un sel hydrosoluble d'oxine, ou de ses derives halogenes ou sulfones, produits ainsi marques, procede de marquage des elements figures du sang, et medicaments ainsi obtenus

Info

Publication number
FR2390408A1
FR2390408A1 FR7714396A FR7714396A FR2390408A1 FR 2390408 A1 FR2390408 A1 FR 2390408A1 FR 7714396 A FR7714396 A FR 7714396A FR 7714396 A FR7714396 A FR 7714396A FR 2390408 A1 FR2390408 A1 FR 2390408A1
Authority
FR
France
Prior art keywords
marking
blood
radioactive isotope
products
labelled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR7714396A
Other languages
English (en)
Inventor
Groupe De Recherche Pour Grami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signify France SAS
Original Assignee
Philips France SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philips France SAS filed Critical Philips France SAS
Priority to FR7714396A priority Critical patent/FR2390408A1/fr
Publication of FR2390408A1 publication Critical patent/FR2390408A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21H—OBTAINING ENERGY FROM RADIOACTIVE SOURCES; APPLICATIONS OF RADIATION FROM RADIOACTIVE SOURCES, NOT OTHERWISE PROVIDED FOR; UTILISING COSMIC RADIATION
    • G21H5/00—Applications of radiation from radioactive sources or arrangements therefor, not otherwise provided for 
    • G21H5/02—Applications of radiation from radioactive sources or arrangements therefor, not otherwise provided for  as tracers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un procédé de marquage par un isotope radioactif d'un sel hydrosoluble d'oxine, ou de ses dérivés halogénés ou sulfonés, ainsi que le produit chimique obtenu selon ce procédé. L'invention décrit egalement un procédé de marquage des éléments figurés du sang, et les produits pharmaceutiques ainsi obtenus. L'invention a trait aux applications médicales de ces produits radioactifs, notamment la visualisation des foyers thrombo-emboliques récents et des abcès et les déterminations de volumes hématiques sanguins. Application : produits pharmaceutiques.
FR7714396A 1977-05-11 1977-05-11 Procede de marquage par un isotope radioactif d'un sel hydrosoluble d'oxine, ou de ses derives halogenes ou sulfones, produits ainsi marques, procede de marquage des elements figures du sang, et medicaments ainsi obtenus Withdrawn FR2390408A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7714396A FR2390408A1 (fr) 1977-05-11 1977-05-11 Procede de marquage par un isotope radioactif d'un sel hydrosoluble d'oxine, ou de ses derives halogenes ou sulfones, produits ainsi marques, procede de marquage des elements figures du sang, et medicaments ainsi obtenus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7714396A FR2390408A1 (fr) 1977-05-11 1977-05-11 Procede de marquage par un isotope radioactif d'un sel hydrosoluble d'oxine, ou de ses derives halogenes ou sulfones, produits ainsi marques, procede de marquage des elements figures du sang, et medicaments ainsi obtenus

Publications (1)

Publication Number Publication Date
FR2390408A1 true FR2390408A1 (fr) 1978-12-08

Family

ID=9190656

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7714396A Withdrawn FR2390408A1 (fr) 1977-05-11 1977-05-11 Procede de marquage par un isotope radioactif d'un sel hydrosoluble d'oxine, ou de ses derives halogenes ou sulfones, produits ainsi marques, procede de marquage des elements figures du sang, et medicaments ainsi obtenus

Country Status (1)

Country Link
FR (1) FR2390408A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0017355A3 (en) * 1979-03-21 1981-01-28 Amersham International Plc Indium-iii oxine complex composition
FR2474314A1 (fr) * 1979-12-31 1981-07-31 Byk Mallinckrodt Cil Bv Solution aqueuse de dosage radiologique pour animaux a sang chaud
EP0096871A3 (fr) * 1982-06-14 1984-03-28 Yale University Composition pour faire une image de cellules sanguines
WO1991014664A1 (fr) * 1990-03-23 1991-10-03 Robert Charles Hider Complexes metalliques
WO1997025074A3 (fr) * 1996-01-12 1997-11-13 Redcell Inc Ancres de proteines seriques et cellulaires destinees a l'imagerie diagnostique

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0017355A3 (en) * 1979-03-21 1981-01-28 Amersham International Plc Indium-iii oxine complex composition
US4335095A (en) * 1979-03-21 1982-06-15 The Radiochemical Centre Limited Indium-111 oxine complex composition
FR2474314A1 (fr) * 1979-12-31 1981-07-31 Byk Mallinckrodt Cil Bv Solution aqueuse de dosage radiologique pour animaux a sang chaud
EP0096871A3 (fr) * 1982-06-14 1984-03-28 Yale University Composition pour faire une image de cellules sanguines
WO1991014664A1 (fr) * 1990-03-23 1991-10-03 Robert Charles Hider Complexes metalliques
WO1997025074A3 (fr) * 1996-01-12 1997-11-13 Redcell Inc Ancres de proteines seriques et cellulaires destinees a l'imagerie diagnostique

Similar Documents

Publication Publication Date Title
Roth et al. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein.
Stokke et al. Methylmalonic acidemia A new inborn error of metabolism which may cause fatal acidosis in the neonatal period
Holtzman et al. Studies on the rate of release and turnover of ceruloplasmin and apoceruloplasmin in rat plasma
US4692435A (en) Mucopolysaccharide composition having a regulatory action on coagulation, medicament containing same and process of preparation
Holtzman et al. Identification of an apoceruloplasmin-like substance in the plasma of copper-deficient rats
Bowman et al. The metabolism of Plasmodium berghei, the malaria parasite of rodents. 2. An effect of mepacrine on the metabolism of glucose by the parasite separated from its host cell
Graham et al. Utilization of the antihemophilic factor during clotting of canine blood and plasma
Margolis Activation of a permeability factor in plasma by contact with glass
US3897309A (en) Process for removing pyrogenic material from aqueous solutions
Salem et al. Heparin induced thrombocytopenia. variable dependent platelet aggregating factor
US4443426A (en) Blood agent
McIlwain Properties of preparations from the central nervous system which degrade coenzymes I and II; their connexion with carbohydrate metabolism
Gerber et al. The ability of nonsteroid anti-inflammatory compounds to accelerate a disulfide interchange reaction of serum sulfhydryl groups and 5, 5′-dithiobis (2-nitrobenzoic acid)
Park et al. A study of the effect of anticoagulants on [3H] vitamin K1 metabolism and prothrombin complex activity in the rabbit
Spaet et al. Inactivation of thromboplastin in human blood
Roubenoff et al. Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukemia with cytosine arabinoside, daunorubicin, and m‐AMSA
Miller et al. Influence of phenytoin on theophylline clearance
US4286063A (en) Method for producing thrombolytic preparation
Corn Effect of thrombin, adenosine diphosphate, connective tissue, and endotoxin on platelet glycolysis
Ke et al. Studies on the physico-chemical inactivation of rabbit interferons
Lewis Effects of Epsilon Amino Caproic Acid (EACA) on Survival of Fibrinogen I131 and on Fibrinolytic and Coagulation Factors in Dogs.
Seegers et al. Partial activation of purified prothrombin: Derivation of autoprothrombin I with use of autoprothrombin C
Tager The comparative action of dicumarol and of phenylindanedione on the coagulase reacting factor and on prothrombin
MEYER Historical data regarding the experiences with coumarin anticoagulants at the University of Wisconsin Medical School
Sills et al. Consumptive coagulopathy: a complication of therapy of solid tumors in childhood

Legal Events

Date Code Title Description
ST Notification of lapse